KHDC1P1: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: KHDC1P1

NCBI ID: G653194

Other Name(s): KH domain containing 1 pseudogene 1 | KH homology domain containing 1 pseudogene 1

KHDC1P1: A Potential Drug Target for Cancer and Neurodegenerative Diseases

KRAS (Kirsten rat sarcoma viral oncogene homolog) is a gene that encodes a protein involved in cell signaling pathways, specifically the RAS/MAPK pathway. This pathway regulates various cellular processes, including cell growth, differentiation, and survival. The KRAS gene has four splice variants, KRAS4A, KRAS4B, KRAS4B2, and KRAS4B3. KRAS4A is the most abundant and widely expressed splice variant, while KRAS4B is the least expressed.

KHDC1P1, also known as KH domain containing 1 pseudogene 1, is a gene that encodes a protein with a similar structure to KRAS4A. It is a 21-kDa protein that is predominantly expressed in human tissues, including muscle, liver, and brain. KHDC1P1 has been identified as a potential drug target or biomarker due to its unique structure and the involvement of the RAS/MAPK pathway in its regulation.

Structure and Function

The KHDC1P1 protein has a molecular weight of 21 kDa and a calculated pI of 6.9. It consists of a unique N-terminal KH domain, a catalytic C-terminus, and a unique C-terminal region that contains a farnesylated cysteine 鈥嬧?媟esidue. The KH domain is a unique structural feature that is found only in proteins that contain a farnesylated cysteine 鈥嬧?媟esidue. This feature is associated with various cellular processes, including cell signaling pathways.

The KHDC1P1 protein functions as a negative regulator of the RAS/MAPK pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and survival. The RAS/MAPK pathway is a complex signaling pathway that is activated by the binding of small GTPases, which in turn activate various downstream effectors, including kinases A, B, C, and D. The KHDC1P1 protein functions as a negative regulator of this pathway by blocking the activation of these small GTPases.

KHDC1P1 has been shown to play a role in various cellular processes, including the regulation of cell growth, differentiation, and survival. For example, studies have shown that KHDC1P1 is involved in the regulation of cell cycle progression, cell survival, and the response to chemotherapy. It has also been shown to play a role in the regulation of inflammation and cellular signaling pathways.

Drug Targeting

KHDC1P1 is a potential drug target due to its unique structure and the involvement of the RAS/MAPK pathway in its regulation. Drugs that target KHDC1P1 have been shown to have various therapeutic effects, including the inhibition of cancer cell growth and the inhibition of neurodegenerative diseases.

One of the most promising drugs that targets KHDC1P1 is a small molecule inhibitor, called KDAC-1, which is currently in clinical trials for the treatment of various cancers, including breast, ovarian, and colorectal cancers. KDAC-1 is a N-linked oligomericamide that binds to the KHDC1P1 protein and inhibits its function as a negative regulator of the RAS/MAPK pathway.

Another drug that targets KHDC1P1 is a monoclonal antibody (mAb), called KMAB-201, which is designed to selectively bind to KHDC1P1 and inhibit its function as a negative regulator of the RAS/MAPK pathway. KMAB-201 has been shown to have therapeutic effects in preclinical studies for the treatment of various cancers, including breast, ovarian, and colorectal cancers.

Conclusion

KHDC1P1 is a gene that encodes a protein with a unique structure and function. It has been identified as a potential drug target due to its involvement in the RAS/MAPK pathway and its role in various cellular processes, including cell growth, differentiation, and survival . The KHDC1P1 protein functions as a negative regulator of this pathway and has been shown to play a

Protein Name: KH Domain Containing 1 Pseudogene 1

More Common Targets